(Q39466320)

12 September 2017

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment (English)

1 reference

12 September 2017

0 references

35

1 reference

12 September 2017

36

Ray Borrow

1 reference

12 September 2017

30

Rino Rappuoli

1 reference

12 September 2017

2

Muhamed-Kheir Taha

1 reference

12 September 2017

14

Matthias Frosch

1 reference

12 September 2017

29

Mariagrazia Pizza

1 reference

12 September 2017

13

Cecilia Fazio

1 reference

12 September 2017

32

Maurizio Comanducci

1 reference

12 September 2017

10

Stefania Bambini

1 reference

12 September 2017

7

Dominique A Caugant

1 reference

12 September 2017

Marzia Monica Giuliani

17

object named as

Marzia M Giuliani

1 reference

12 September 2017

31

Davide Serruto

1 reference

12 September 2017

23

Alessandro Muzzi

1 reference

12 September 2017

5

Heike Claus

1 reference

12 September 2017

18

Eva Hong

1 reference

12 September 2017

21

Jay Lucidarme

1 reference

12 September 2017

1

Ulrich Vogel

1 reference

12 September 2017

Giuseppe Boccadifuoco

33

object named as

Giuseppe Boccadifuoco

1 reference

12 September 2017

19

Morgan Ledroit

1 reference

12 September 2017

4

Jamie Findlow

1 reference

12 September 2017

16

Stefanie Gilchrist

1 reference

12 September 2017

6

Paola Stefanelli

1 reference

12 September 2017

11

Anna Carannante

1 reference

12 September 2017

24

Jan Oksnes

1 reference

12 September 2017

Julio A Vazquez

3

1 reference

12 September 2017

Paula Kriz

8

1 reference

12 September 2017

Raquel Abad

9

1 reference

12 September 2017

Ala Eddine Deghmane

12

1 reference

12 September 2017

Giacomo Frosi

15

1 reference

12 September 2017

Pietro G Lovaglio

20

1 reference

12 September 2017

Martin Musilek

22

1 reference

12 September 2017

Fabio Rigat

25

1 reference

12 September 2017

Luca Orlandi

26

1 reference

12 September 2017

Maria Stella

27

1 reference

12 September 2017

Danielle Thompson

28

1 reference

12 September 2017

John J Donnelly

34

1 reference

12 September 2017

13 February 2013

1 reference

Lancet Infectious Diseases

12 September 2017

1 reference

12 September 2017

13

1 reference

12 September 2017

5

1 reference

12 September 2017

416-425

1 reference

Advances in the development of vaccines against Neisseria meningitidis

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Serogroup B meningococcal vaccines-an unfinished story

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Virulence factors of gram-negative bacteria in sepsis with a focus on Neisseria meningitidis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Recombination within natural populations of pathogenic bacteria: short-term empirical estimates and long-term phylogenetic consequences

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

NadA diversity and carriage in Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

In the NadR regulon, adhesins and diverse meningococcal functions are regulated in response to signals in human saliva

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Multilocus sequence typing for global surveillance of meningococcal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

The challenge of post-implementation surveillance for novel meningococcal vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970006-9

7 January 2021

10.1016/S1473-3099(13)70006-9

Identifiers

DOI

1 reference

12 September 2017

1 reference